Page 249 of 287: studies 2,481 to 2,490 of 2,864, newest first. Back to the cannabis overview
Cannabinoids and the Brain March 1, 2017 Linda A. Parker
Global activation of CB1 receptors produces actions on hippocampal neurons, which results in interference with short tem memory and consolidation of memories that are currently being processed. However, such CB1 receptor activation does not impair recall of previously established memories. Evidence suggests that the acute effects of cannabis on memory depend in part on the type of cannabis that...
Cannabinoids and the Brain March 1, 2017 Linda A. Parker
Clearly the majority of people who use marijuana do not develop schizophrenia. Yet, the human literature suggests that there is a modest association between cannabis exposure (particularly in adolescence) and later development of schizophrenia--whether or not this association is causal is hotly debated. This chapter reviews some of the evidence for and against such a causal relationship. The...
Journal of Addiction Research February 7, 2017
Synthetic cannabinoids (SC) are analogs of natural cannabinoids that are chemically synthesized. These compounds are used frequently in the community as illicit substances. Literature review indicates that its use is increasing due to its easy accessibility despite it being placed under Schedule I of the Synthetic Drug Abuse Prevention Act of 2012. SC is readily found in most inner urban...
BMJ January 25, 2017 Derek K. Tracy, David M Wood, David Baumeister 117 citations
Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Novel psychoactive substances: types, mechanisms of action, and...
Clinical Pharmacology & Therapeutics January 13, 2017 Marilyn A. Huestis, Rachel F. Tyndale 12 citations
This “Designer Drugs 2.0” issue of Clinical Pharmacology & Therapeutics focuses on novel psychoactive substances, primarily cannabinoids and cathinones, and the repurposing of established psychoactive compounds (e.g., modafinil, psilocybin, lysergic acid diethylamide, and 3,4‐methylenedioxymethamphetamine) that simultaneously offer new pharmacotherapies and pose serious health problems. Novel...
Current Topics in Behavioral Neurosciences 2017 S. Tai, William E Fantegrossi
Commercial preparations containing synthetic cannabinoids (SCBs) are rapidly emerging as drugs of abuse. Although often assumed to be “safe” and “legal” alternatives to cannabis, reports indicate that SCBs induce toxicity not often associated with the primary psychoactive component of marijuana, Δ9-tetrahydrocannabinol (Δ9-THC). This chapter will summarize the evidence that use of SCBs poses...
Brain Research January 1, 2017 Diana Dow-Edwards, Lindsay Silva
Marijuana use during adolescence has reached virtually every strata of society. The general population has the perception that marijuana use is safe for mature people and therefore is also safe for developing adolescents. However, both clinical and preclinical research shows that marijuana use, particularly prior to age 16, could have long-term effects on cognition, anxiety and stress-related...
Molecular Psychiatry January 2017 G A Vargish, K A Pelkey, X Yuan et al.
Placental transfer of Δ9-tetrahydrocannabinol (THC) during pregnancy has the potential to interfere with endogenous cannabinoid (CB) regulation of fetal nervous system development in utero. Here we examined the effect of maternal CB intake on mouse hippocampal interneurons largely focusing on cholecystokinin-expressing interneurons (CCK-INTs), a prominent CB subtype-1 receptor (CB1R) expressing...
Cannabis and Cannabinoid Research 2017 David L Arndt, Harriet de Wit
Introduction: Cannabidiol (CBD) is a nonpsychoactive constituent of whole plant cannabis that has been reported to reduce anxiety-like behaviors in both pre-clinical and human laboratory studies. Yet, no controlled clinical studies have demonstrated its ability to reduce negative mood or dampen responses to negative emotional stimuli in humans. The objective of this study was to investigate the...
Journal of Psychoactive Drugs 2017 Stephen L Thornton, David Lisbon, Thomas Lin et al.
Methoxetamine and 3-methoxy-phencyclidine are novel arylcyclohexylamines whose use and clinical toxicity are poorly reported in the medical literature. We report a case of analytically confirmed use of both methoxetamine and 3-methoxy-phencyclidine. A 27-year-old male presented 10 hours after insufflating an Internet-obtained powder. He was hypertensive, tachycardic, and demonstrated...